FPA150

March 6, 2019

FPA150 Trial Begins Dosing Ovarian, Breast, Endometrial Cancer Patients

News

Five Prime Therapeutics’ ongoing Phase 1 clinical trial has advanced to its Phase 1b expansion portion, in which researchers have begun giving breast, ovarian, and endometrial cancer patients an optimal dose ... Read more

October 26, 2018

Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients

News

The Phase 1a/1b trial evaluating Five Prime Therapeutics‘ checkpoint inhibitor FPA150 in patients with advanced solid cancers has begun dosing patients ahead of schedule, the company announced. FPA150 is an antibody that targets ... Read more